6LK0

Crystal structure of human wild type TRIP13


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.60 Å
  • R-Value Free: 0.265 
  • R-Value Work: 0.197 
  • R-Value Observed: 0.200 

wwPDB Validation   3D Report Full Report


This is version 1.3 of the entry. See complete history


Literature

A Small-Molecule Inhibitor Targeting TRIP13 Suppresses Multiple Myeloma Progression.

Wang, Y.Huang, J.Li, B.Xue, H.Tricot, G.Hu, L.Xu, Z.Sun, X.Chang, S.Gao, L.Tao, Y.Xu, H.Xie, Y.Xiao, W.Yu, D.Kong, Y.Chen, G.Sun, X.Lian, F.Zhang, N.Wu, X.Mao, Z.Zhan, F.Zhu, W.Shi, J.

(2020) Cancer Res 80: 536-548

  • DOI: https://doi.org/10.1158/0008-5472.CAN-18-3987
  • Primary Citation of Related Structures:  
    6LK0

  • PubMed Abstract: 

    The AAA-ATPase TRIP13 drives multiple myeloma progression. Here, we present the crystal structure of wild-type human TRIP13 at a resolution of 2.6 Å. A small-molecule inhibitor targeting TRIP13 was identified on the basis of the crystal structure. The inhibitor, designated DCZ0415, was confirmed to bind TRIP13 using pull-down, nuclear magnetic resonance spectroscopy, and surface plasmon resonance-binding assays. DCZ0415 induced antimyeloma activity in vitro, in vivo , and in primary cells derived from drug-resistant patients with myeloma. The inhibitor impaired nonhomologous end joining repair and inhibited NF-κB activity. Moreover, combining DCZ0415 with the multiple myeloma chemotherapeutic melphalan or the HDAC inhibitor panobinostat induced synergistic antimyeloma activity. Therefore, targeting TRIP13 may be an effective therapeutic strategy for multiple myeloma, particularly refractory or relapsed multiple myeloma. SIGNIFICANCE: These findings identify TRIP13 as a potentially new therapeutic target in multiple myeloma.


  • Organizational Affiliation

    Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Pachytene checkpoint protein 2 homolog433Homo sapiensMutation(s): 0 
Gene Names: TRIP13PCH2
UniProt & NIH Common Fund Data Resources
Find proteins for Q15645 (Homo sapiens)
Explore Q15645 
Go to UniProtKB:  Q15645
PHAROS:  Q15645
GTEx:  ENSG00000071539 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ15645
Sequence Annotations
Expand
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.60 Å
  • R-Value Free: 0.265 
  • R-Value Work: 0.197 
  • R-Value Observed: 0.200 
  • Space Group: P 65
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 90.762α = 90
b = 90.762β = 90
c = 114.36γ = 120
Software Package:
Software NamePurpose
REFMACrefinement
HKL-2000data collection
HKL-2000data reduction
HKL-2000data scaling
Cootmodel building
SHELXCDphasing

Structure Validation

View Full Validation Report



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
National Natural Science Foundation of China (NSFC)China81870158

Revision History  (Full details and data files)

  • Version 1.0: 2020-01-22
    Type: Initial release
  • Version 1.1: 2020-01-29
    Changes: Database references
  • Version 1.2: 2020-02-12
    Changes: Database references
  • Version 1.3: 2024-03-27
    Changes: Data collection, Database references